Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03132636 2025-04-08

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Phase 2 Completed

138 enrolled 21 charts 1 FDA

Dermatologic

Carcinoma, Basal Cell

NCT03257267 2025-04-08

Study of Cemiplimab in Adults With Cervical Cancer

Phase 3 Completed

608 enrolled 18 charts

Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT03409614 2025-03-13

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3 Completed

790 enrolled 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03192345 2024-08-07

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Phase 1 Completed

161 enrolled

Other solid neoplasm

Malignant Solid Tumor

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Phase 1/2 Completed

109 enrolled 27 charts

Plasma cell

Multiple Myeloma

NCT03005782 2024-05-01

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Phase 1 Completed

333 enrolled

Tumor-Agnostic

Neoplasms

NCT05302297 2022-12-13

TOSCA

Completed

305 enrolled

Tumor-Agnostic

Neoplasms

NCT02423863 2020-12-17

Poly-ICLC

Phase 2 Completed

26 enrolled

DermatologicHead & NeckSarcoma

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT03002376 2020-04-20

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

Phase 1 Completed

47 enrolled

Dermatologic

Melanoma

NCT03198130 2020-03-19

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Phase 1 Completed

33 enrolled

Recurrent Squamous Cell Carcinoma of Head

NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Phase 1 Completed

398 enrolled

Advanced Cancer